¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Neuromuscular Manifestations"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • neuromuscular
    ½Å°æ±Ù(À°)-
  • neuromuscular antagonist
    ½Å°æ±Ù(À°)´ëÇ×Á¦
  • neuromuscular blocker
    ½Å°æ±Ù(À°)Â÷´ÜÁ¦
  • neuromuscular coordination
    ½Å°æ±Ù(À°)Çùµ¿
  • neuromuscular disease
    ½Å°æ±Ù(À°)º´
  • neuromuscular disorder
    ½Å°æ±Ù(À°)Àå¾Ö, ½Å°æ±Ù(À°)Áúȯ
  • neuromuscular dysfunction
    ½Å°æ±Ù(À°)±â´ÉÀÌ»ó
  • neuromuscular junction
    ½Å°æ±Ù(À°)ÀÌÀ½ºÎ
  • neuromuscular monitoring
    ½Å°æ±Ù(À°)°¨½Ã
  • neuromuscular receptor
    ½Å°æ±Ù(À°)¼ö¿ëü
  • neuromuscular spindle
    ½Å°æ±Ù(À°)¹æÃß
  • neuromuscular synapse
    ½Å°æ±Ù(À°)½Ã³À½º, ½Å°æ±Ù(À°)¿¬Á¢
  • neuromuscular transmission
    ½Å°æ±Ù(À°)Àü´Þ
  • proprioceptive neuromuscular facilitation
    °íÀ¯°¨°¢½Å°æ±ÙÀ°ÃËÁø
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • neuromuscular disorder
    ½Å°æ±ÙÀ°Àå¾Ö, ½Å°æ±ÙÀ°Áúȯ
  • neuromuscular
    ½Å°æ±ÙÀ°-
  • neuromuscular synapse
    ½Å°æ±ÙÀ°¿¬Á¢
  • neuromuscular spindle
    (¢¡muscle spindle) ±ÙÀ°¹æÃß
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • neuromuscular antagonist
    ½Å°æ±ÙÀ°´ëÇ×Á¦
  • neuromuscular blocker
    ½Å°æ±ÙÀ°Â÷´ÜÁ¦
  • neuromuscular coordination
    ½Å°æ±ÙÀ°Çùµ¿
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø½Å°æ±ÙÂ÷´ÜÁ¦
  • neuromuscular disease
    ½Å°æ±ÙÀ°º´
  • neuromuscular disorder
    ½Å°æ±ÙÀ°Àå¾Ö, ½Å°æ±ÙÀ°Áúȯ
  • neuromuscular dysfunction
    ½Å°æ±ÙÀ°±â´ÉÀå¾Ö
  • neuromuscular junction
    ½Å°æ±ÙÀ°ÀÌÀ½ºÎ
  • neuromuscular monitoring
    ½Å°æ±ÙÀ°°¨½Ã
  • neuromuscular
    ½Å°æ±ÙÀ°-
  • neuromuscular receptor
    ½Å°æ±ÙÀ°¼ö¿ëü
  • neuromuscular spindle
    (¢¡muscle spindle) ±ÙÀ°¹æÃß
  • neuromuscular stimulant
    ½Å°æ±ÙÀ°ÀÚ±ØÁ¦
  • neuromuscular synapse
    ½Å°æ±ÙÀ°¿¬Á¢
  • neuromuscular transmission
    ½Å°æ±ÙÀ°Àü´Þ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • NMU= neuromuscular unit
    ½Å°æ±Ù´ÜÀ§.
  • prejunctional neuromuscular receptor
    ½Å°æ±ÙÁ¢ÇÕÀü¼ö¿ëü
  • proprioceptive neuromuscular facilita
    °íÀ¯¼ö¿ëü½Å°æ±ÙÃËÁø(ͳêóáôé»ô÷ãêÌèÐÉõµ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø¼º ½Å°æ±ÙºÀ¼â¾à¹°.
  • neuromuscular
    ½Å°æ±Ù(ãêÌèÐÉ)ÀÇ.
  • neuromuscular antagonist
    ½Å°æ±Ù±æÇ×Á¦.
  • neuromuscular blocker
    ½Å°æ±ÙÂ÷´Ü<ºÀ¼â>Á¦.
  • neuromuscular blocker
    ½Å°æ±ÙÂ÷´ÜÁ¦.
  • neuromuscular blocking agent
    ½Å°æ±ÙÂ÷´Ü<ºÀ¼â>Á¦(¾à).
  • neuromuscular blocking agent
    ½Å°æ±ÙÂ÷´ÜÁ¦, ½Å°æ±ÙÂ÷´Ü¾à(~ó´Ó¨å·).
  • neuromuscular coordination
    ½Å°æ±ÙÇùÁ¶¼º(~úððààõ)<Á¶È­¼º>.
  • neuromuscular disease
    ½Å°æ±ÙÀ°Áúȯ.
  • neuromuscular disorder
    ½Å°æ±ÙÀ°Áúȯ
  • neuromuscular disorder
    ½Å°æ±ÙÁúȯ(~òðü´).
  • neuromuscular dysfunction
    ½Å°æ±Ù ±â´ÉºÎÀü, ¡­±â´ÉÀå¾Ö
  • neuromuscular junction
    ½Å°æ±ÙÁ¢ÇÕ(ºÎ)(~ïÈùêÝ»).
  • neuromuscular junction
    ½Å°æ±ÙÁ¢ÇÕ(ºÎ)(¡­ÐÉïÈùêÝ»)
  • neuromuscular monitoring
    ½Å°æ±Ù°¨½Ã
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Neuromuscular terminal of spindle
    ¹æÃ߽Űæ±ÙÀ°Á¾¸»
    [¿¾ ¿ë¾î] ¹æÃß»ó½Å°æ±ÙÁ¾¸»
  • Neuromuscular spindle
    ½Å°æ±ÙÀ°¹æÃß
    [¿¾ ¿ë¾î] ½Å°æ±Ù¹æÃß
  • Neuron of neuromuscular spindle
    ½Å°æ±ÙÀ°¹æÃ߽Ű漼Æ÷
    [¿¾ ¿ë¾î] ½Å°æ±Ù¹æÃ߽Ű漼Æ÷
  • Neuromuscular terminal
    ½Å°æ±ÙÀ°Á¾¸»
    [¿¾ ¿ë¾î] ½Å°æ±Ù¿¬Á¢Á¾¸»
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • neuromuscular disease
    ½Å°æ±ÙÀ° Áúȯ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
NMB neuromedin B; neuromuscular blockade; neuromuscular blocking; neuromuscular blocker/blocking [drug, ...
NMT neuromuscular tension; neuromuscular transmission; N-methyltransferase; N-myristoyltransferase; no m...
FNS frontier nursing service; functional neuromuscular stimulation
FSN functional stimulation, neuromuscular
NFND National Foundation for Neuromuscular Diseases
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
FNS Functional Neuromuscular Stimulation
NM Neuromuscular
NMD Neuromuscular Diseases
NMB Neuromuscular block
NMB Neuromuscular blockade
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø¼º ½Å°æ±Ù ºÀ¼â ¾à¹°
  • neuromuscular
    ±Ù½Å°æ¼º, ½Å°æ±ÙÀÇ
    ½Å°æ°ú ±ÙÀ° ¸ðµÎ¿¡ °üÇÑ.
  • neuromuscular antagonist
    ½Å°æ±Ù ±æÇ×Á¦
  • neuromuscular blocking agent
    ½Å°æ±Ù Â÷´ÜÁ¦, ½Å°æ±Ù Â÷´Ü ¾à
  • neuromuscular coordination
    ½Å°æ±Ù ÇùÁ¶¼º, ½Å°æ±Ù Á¶È­¼º
  • neuromuscular disorder
    ±Ù½Å°æ°è Áúȯ, ±Ù½Å°æ Àå¾Ö, ½Å°æ±Ù Áúȯ
  • neuromuscular function
    ±Ù½Å°æ ±â´É
  • neuromuscular junction
    ½Å°æ±Ù Á¢ÇÕ, ½Å°æ±Ù Á¢ÇÕºÎ
  • neuromuscular protecting mechanism
    ±Ù½Å°æ°èÀÇ º¸È£ ±âÀü
  • neuromuscular reflex activity
    ±Ù½Å°æ ¹Ý»ç Ȱµ¿
  • neuromuscular spindle
    ½Å°æ±Ù ¹æÃß
  • neuromuscular symptom
    ½Å°æ Ç÷°ü Áõ»ó
  • neuromuscular system
    ±Ù½Å°æ°è, ½Å°æ ±ÙÀ°°è
  • neuromuscular unit
    ½Å°æ±Ù ´ÜÀ§
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
amyloidosis: bone manifestations <radiology> Joint pain without radiographic findings, osteoporosis, especially in axial skeleton, lytic lesions that destroy cortex and invade soft tissue, wrist, scaphoid and lunate lesions that may extend into the carpal tunnel, inducing the classic complaints of carpal tunnel syndrome amyloid arthropathy Differential diagnosis: pigmented villonodular synovitis, synovial chondromatosis, rheumatoid arthritis, TB
(12 Dec 1998)
amyloidosis: gastrointestinal manifestations <radiology> Oesophagus, loss of peristalsis, megaesophagus, stomach, small and rigid (simulate linitis plastica), effaced rugal pattern, diminished/absent peristalsis, may be localised to antrum, amyloidoma: well defined submucosal mass, small bowel, diffuse form (more common), diffuse, uniform thickening of valvulae conniventes, broadened flat undulated mucosal folds (mucosal atrophy), jejunalization of ileum, impaired motility, small bowel dilatation, localised form: multiple small deposits; associated with pseudoobstruction, colon, psudopolyps
(12 Dec 1998)
rheumatoid arthritis: joint manifestations <radiology> Early signs: fusiform periarticular soft tissue swelling (result of effusion), regional osteoporosis (disuse and local hyperaemia), widened joint space, marginal and central bone erosion (base of 4th proximal phalanx most common), change in ulnar styloid and distal radioulnar joint, atlantoaxial dislocation, giant synovial cysts late signs: flexion/extension contractures with ulnar subluxation/dislocation, destruction/fusion of joints, elevation of humeral heads (tear/atrophy of rotator cuff), resorption of distal clavicle, erosion of superior margins of posterior portions of 3-5th ribs, destruction/narrowing of disc spaces, destruction of zygapophyseal joints without osteophyte formation, resorption of spinous process, protrusio acetabuli (from osteoporosis)
(12 Dec 1998)
crohn disease: extraintestinal manifestations <radiology> Fatty liver, gallstones (28-34%), risk 3-5X higher than expected, secondary to malabsorption of bile salts in terminal ileum, correlation with length of diseased ileum and duration of disease, sclerosing cholangitis, bile duct carcinoma, amyloidosis, urolithiasis: oxalate/uric acid stones, migratory arthritis (5-20%), sacroilitis, ankylosing spondylitis, erythema nodosum, uveitis see: Crohn disease
(12 Dec 1998)
sickle cell anaemia: bone manifestations <radiology> 8-13% of blacks carry sickling factor, symptoms: chronic ulcers, pain crises, many infections, priapism X-ray findings: deossification due to marrow hyperplasia, decreased bone density in skull with widened diploe, H-shaped vertebrae or fish vertebrae, rib notching, thrombosis and infarction, avascular necrosis, especially femoral head, periosteal treatmentn (bone within bone), secondary osteomyelitis, Staph. Aureus greater than Salmonella, dactylitis = hand foot syndrome, growth effects, bone shortening secondary to diminished blood supply, death less than 40y
(12 Dec 1998)
skin manifestations Dermatologic disorders attendant upon non-dermatologic disease or injury.
(12 Dec 1998)
skin manifestations of GI disease <radiology> Pancreatic carcinoma . . . . . . . . Thrombophlebitis migrans, glucagonoma . . . . . . . . . Migratory necrolytic erythema, IBD . . . . . . . . . . . . . . . Pyoderma gangrenosum, sprue / coeliac disease. . . . Dermatitis herpetiformis, Whipple disease . . . . . . . Pigmentation, primary biliary cirrhosis . . . . Exanthemasma, hepatic cirrhosis . . . . . . . . Spider angiomata
(12 Dec 1998)
neurologic manifestations Neurologic disorders attendant upon non-neurologic disease or injury.
(12 Dec 1998)
oral manifestations Disorders of the mouth attendant upon non-oral disease or injury.
(12 Dec 1998)
tuberculosis: gastrointestinal manifestations <radiology> Ileocaecal area, most common site (80-90%), Stierlin sign, Fleischner sign, thickened ileocaecal valve, fissures, ulcers, sinus tracts, fistulas, perforation, colon, segmental involvement; especially on right side, ulcerating colitis with pseudopolyps, hourglass stricture, wall thickening, gastroduodenal area, simultaneous involvement of pylorus and duodenum, stenotic pylorus with gastric outlet obstruction, narrowed antrum (linitis plastica appearance), ulcers, thickened folds, antral fistula, oesophagus, least common site, ulcers, stricture, mass, sinus tracts
(12 Dec 1998)
eye manifestations Ocular disorders attendant upon non-ocular disease or injury.
(12 Dec 1998)
ulcerative colitis: extracolonic manifestations <radiology> Iritis, erythema nodosum, pyoderma gangrenosum, pericholangitis, chronic active hepatitis, primary sclerosing cholangitis, fatty liver, spondylitis, peripheral arthritis, coincidental rheumatoid arthritis, thrombotic complications see: ulcerative colitis
(12 Dec 1998)
neuromuscular <anatomy> Pertaining to muscles and nerves.
(18 Nov 1997)
neuromuscular agents Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (neuromuscular blocking agents), and drugs that act centrally as skeletal muscle relaxants (muscle relaxants, central). Drugs used in the treatment of movement disorders are anti-dyskinesia agents.
(12 Dec 1998)
neuromuscular blockade The intentional interruption of transmission at the neuromuscular junction by external agents, usually neuromuscular blocking agents. It is distinguished from nerve block in which nerve conduction is interrupted rather than neuromuscular transmission. Neuromuscular blockade is commonly used to produce muscle relaxation as an adjunct to anaesthesia during surgery and other medical procedures. It is also often used as an experimental manipulation in basic research. It is not strictly speaking anaesthesia but is grouped here with anaesthetic techniques. The failure of neuromuscular transmission as a result of pathological processes is not included here.
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Neuromuscular Manifestations - »õâ Signs and symptoms associated with diseases of the muscle, neuromuscular junction, or peripheral nerves.
    Synonyms : Manifestations, Muscle Disease, Neuromuscular Signs and Symptoms, Signs and Symptoms, Neuromuscular, Disease Manifestation, Muscle, Disease Manifestations, Muscle, Manifestation, Muscle Disease, Manifestation, Neuromuscular, Manifestations, Neuromuscular
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á